Why Is MODERNA INC (MRNA) Stock Up Today?

Moderna Inc. shares climbed 8.10% to close at $212.95, driven primarily by a multiyear collaboration with Tempus and Merck aimed at commercializing the company's cancer vaccine, intismeran autogene. The move also followed a price target increase from Bank of America, which raised its outlook to $200 from $170.

What Happened

The primary catalyst was the announcement of a partnership between Tempus, a healthcare-technology company, and Moderna to commercialize intismeran autogene. This therapy is currently being evaluated in combination with Merck's Keytruda for patients with completely resected stage IIB-IV melanoma. The collaboration focuses on the potential commercialization of this individualized mRNA cancer therapy, which recently hit a Phase 3 milestone in the INTerpath-001 trial.

In addition to the strategic partnership, Bank of America analysts raised their price target on the stock to $200, up from the previous $170. This valuation adjustment reflects a more positive view of the company's oncology pipeline, which is seen as carrying transformative potential even as the traditional vaccine market cools. The stock's surge brings it to the upper end of its recent trading range, marking a significant reversal from the slight decline seen in the prior eight sessions.

What The Data Shows

Moderna’s market capitalization stands at $78.4 billion, though the company remains unprofitable with a trailing twelve-month EPS of -$8.01 and a net margin of -141.4%. Revenue has declined 27.6% over the same period. Despite these fundamental challenges, the stock printed eight fresh 52-week highs on October 9, 2026, reaching a session high of $213.84.

Intraday volume was 3.3 million shares, which is 0.2 times the three-month daily average, indicating the price move occurred on relatively light volume. Unusual options activity over the last 36 hours included six notable prints, with call premium totaling $4.0 million versus $2.8 million in put premium. The largest single print was $2.0 million. Recent insider filings show five sales totaling $49.2 million over the last 90 days, with no buys recorded. Congressional disclosures in the same period included four buys and four sells.

What To Watch

Investors will monitor the progress of the intismeran autogene trial and the commercialization timeline outlined in the Tempus and Merck collaboration. The stock's proximity to its 52-week high of $212.22 suggests continued volatility as the market digests the new partnership details.